Local Site Tolerability of Multiple Dose Treatment With Deltoid Intramuscular Injection of RISPERDAL CONSTA in Subjects With Chronic Schizophrenia.
Sponsor study identifier
interventional
53
0 countries
N/A
Study Start
February 2006
Date type not reportedThis date has not been verified as actual or estimated.
Primary Completion
Not reported
Date not reportedStudy Completion
September 2006
Actual (reported)The purpose of this study is to examine the discontinuation rate of schizophrenia patients receiving multiple sequential 2 mL injections of long acting injectable risperidone (an atypical antipsychotic medication) when administered into the deltoid muscle once every 2 weeks.
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
September 2006
Actual (reported)Click on a node to explore related trials.
Some registry-reported names shown below are not yet linked in this graph.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
February 2006
Date type not reportedThis date has not been verified as actual or estimated.
September 2006
Actual (reported)January 22, 2009
Actual (reported)January 26, 2009
Actual (reported)The proportion of patients who discontinued from the study after having received at least 2 deltoid injections will be recorded.
Reasons for discontinuation, patient rated local site injection pain and investigator rated local site injection reaction will be assessed at predefined times throughout the study.
Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.
Johnson & Johnson Pharmaceutical Research & Development, L.L. C. Clinical Trial
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
53 participants (actual enrollment reported by the registry).
First Submitted
January 22, 2009
First Posted
January 26, 2009
Study Start
February 2006
Date type not reportedThis date has not been verified as actual or estimated.
Investigate Risperidone for the Treatment of Schizophrenia in Adolescents
Contact the study team to confirm eligibility.
Study Completion
September 2006
Actual (reported)Last Updated
May 18, 2011
Record last verified: 2010-03
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: